YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
AnaptysBio, Inc. previously reported fourth-quarter and six-month 2026 results showing net income of US$183.88 million for the quarter and US$131 million for the half-year, with basic earnings per share from continuing operations rising to…
Investing.com - U.S. stock index futures steadied on Tuesday, following a strong session on Wall Street that saw the benchmark S&P 500 post its best day since August, helped by gains in artificial intelligence-linked stocks. Still guessing…
The S&P 500 Index ($SPX) (SPY) is down by -0.03% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down by -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.20%. December E-mini S&P futures (ESZ26) are down -0.05%, and Decembe…
If last week was the setup (consumer and wholesale inflation data, surging oil prices), then this week is the main event, with all eyes squarely on Washington, D.C., where the Federal Reserve on Wednesday will announce its latest rate deci…
Alphyn Capital Management, an investment management firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. The fund's Master Account returned 0.6% net in the quarter compared to 15.2% for the S&P500. As…
GSK plc GSK announced that the FDA has accepted for review its supplemental biologics license application (sBLA) seeking approval for its oncology drug, Jemperli (dostarlimab), for a new cancer indication. The sBLA is seeking approval of J…
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating pro…
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment i…
GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), in rectal cancer. The registrational phase II AZUR-1 study evaluated Jemperli for the treatment of patients with s…
* AnaptysBio press release [https://seekingalpha.com/pr/20512254-anaptys-announces-first-quarter-2026-financial-results-and-provides-business-update] (ANAB [https://seekingalpha.com/symbol/ANAB]): Q1 GAAP EPS of -$1.84 misses by $1.04. * C…
AnaptysBio, Inc. Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced appointment…
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. T…
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and We…
Nektar Therapeutics NKTR reported a loss of $1.82 per share for the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.74. In the year-ago quarter, the company had reported a loss of $3.62 cents per share. Total…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
Zoetis, Inc. ZTS delivered first-quarter 2026 adjusted earnings (excluding one-time items) of $1.53 per share, which missed the Zacks Consensus Estimate of $1.61. In the year-ago quarter, the company had delivered adjusted earnings of $1.4…
TG Therapeutics TGTX reported earnings of 17 cents per share (excluding the loss on extinguishment of debt) for the first quarter of 2026, missing the Zacks Consensus Estimate of 23 cents. The company had reported earnings of 3 cents per s…
Mirum Pharmaceuticals MIRM incurred a loss of 39 cents per share (excluding certain one-time expenses) in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 40 cents. The company had reported a loss of 30 ce…
Wall Street expects a year-over-year increase in earnings on lower revenues when AnaptysBio, Inc. (ANAB) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earn…
[GSK -Glaxosmithkline headquarters office building in Poznan.] Magdalena Wygralak GSK plc (GSK [https://seekingalpha.com/symbol/GSK]) subsidiary TESARO said the Delaware Court of Chancery has granted a motion to dismiss AnaptysBio’s (ANAB…
Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point of 42.13. Continue Reading
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index down 0.8% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Health care stocks declined Friday afternoon, with the NYSE Health Care Index down 0.6% and the Stat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
AnaptysBio's (ANAB) board has approved the planned spin-off of First Tracks Biotherapeutics and a re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) has approved the spin-off of First Tracks Biotherapeutics, the company said on Friday. * The new company is expected to begin regular trading on the Nasdaq on April 20, 2026, under…
AnaptysBio, Inc. Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda,…
Adaptive Biotechnologies (ADPT) shares ended the last trading session 5.8% higher at $13.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.9…
AnaptysBio logo Key Points AnaptysBio is moving forward with a near-term split into two public companies — a low-cost royalty company holding Jemperli and future imsidolimab royalties, and a development-focused biopharma company housing AN…
(RTTNews) - AnaptysBio, Inc. (ANAB) yesterday reported its fourth-quarter and full-year 2025 financial results while outlining progress across its immunology pipeline and confirming plans to spin off its biopharma operations into a new pub…
AnaptysBio logo Key Points AnaptysBio plans to split into two publicly traded companies via a dividend to shareholders, currently "tracking towards a Q2 separation" (timing could slip), with the new biopharma company holding clinical progr…
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive…
Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47. Continue Reading
Key Points An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J. Anthony Ware's direct holdings, as reported, reducing his position from 13,530 to 9,630 shares.…
Key Points The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45,738 to 42,088 shares, as re…
Key Points The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45,738 to 42,088 shares, as re…
AnaptysBio (ANAB) said Thursday it has filed a partial motion to dismiss Tesaro's anticipatory breac PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…